

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF TEXAS
TYLER DIVISION**

POZEN INC.

Plaintiff,

VS.

**PAR PHARMACEUTICAL, INC.,
ALPHAPHARM PTY LTD.,
TEVA PHARMACEUTICALS
USA INC., DR. REDDY'S LABS., INC.**

Defendants.

[illegible]

CASE NO. 6:08 CV 437
PATENT CASE

**CONSOLIDATED WITH
CASE NO. 6:09 CV 3 AND
CASE NO. 6:09 CV 182**

FINAL JUDGMENT

Pursuant to Rule 58 of the Federal Rules of Civil Procedure, consistent with the Court's contemporaneous Findings of Fact and Conclusions of Law and the entirety of the record available to this Court, the Court **ORDERS AND ENTERS FINAL JUDGMENT** as follows:

- Defendants Par Pharmaceutical Inc. (“Par”), Alphapharm Pty Ltd. (“Alphapharm”), and Dr. Reddy’s Laboratories, Inc. (“DRL”) infringe U.S. Patent Nos. 6,060,499 (“the ’499 patent”), 6,586,458 (“the ’458 patent”).
- Par and DRL infringe the 7,332,183 patent (“the ’183 patent”).
- The patents-in-suit are not invalid and are enforceable.
- Par, Alphapharm, and DRL shall be enjoined from making, using, importing, selling or offering to sell their ANDA products in the United States or inducing others in the manufacture, use, import, offer to sell or sale of their ANDA products in the United States until the expiration of U.S. Patent Nos. 6,060,499 and 6,586,458.
- Par and DRL are also enjoined until the expiration of the U.S. Patent No. 7,332,183

patent.

- The Court also sets the effective dates of the approval of Par, Alphapharm, and DRL Abbreviated New Drug Applications (“ANDAs”) after the patents-in-suit expire.

So ORDERED and SIGNED this 5th day of August, 2011.

A handwritten signature in black ink, appearing to read 'Leonard Davis', written over a horizontal line.

LEONARD DAVIS
UNITED STATES DISTRICT JUDGE